KLOX Technologies Inc. ("KLOX" or the "Company") released results from its most recent extension trial in Europe for its innovative AC-1 BioPhotonic platform for the treatment of moderate to severe acne vulgaris. Of the 140 million people worldwide who suffer from this chronic and often debilitating dermatological condition, over 20% suffer from moderate to severe forms...